About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Scientists Reveal New Target for Antidepressants

by Kathy Jones on June 1, 2010 at 10:59 PM
Font : A-A+

 Scientists Reveal New Target for Antidepressants

The most detailed picture yet of a key receptor in the brain that influences the effectiveness of serotonin-related antidepressants has been provided by researchers at University of Michigan. The finding paves the way for a more targeted treatment of depression and anxiety with fewer side effects.

Depressive disorders change a person's mood, emotions and physical well-being and can co-occur with anxiety disorders and substance abuse.

Advertisement

"There are big drawbacks in the current therapies for depression. Therapeutic benefits are delayed, there are unwanted side effects, and it's not unusual for depressive symptoms to return," said senior author Dr. John Traynor, professor of pharmacology at the U-M Medical School and director of the U-M Substance Abuse Research Center.

The best current treatments for depression are selective serotonin reuptake inhibitors, or SSRIs. These drugs work by flooding the brain's synapses with serotonin, a neurotransmitter linked with mood, and increasing signalling through the more than 20 serotonin receptors in the brain.
Advertisement

However the team of researchers showed that one particular pathway, the serotonin 5HT1a receptor is linked with antidepressive and anti-anxiety behaviour in mice.

"Rather than activating all serotonin receptors as SSRIs do, one could increase signaling through the one critical serotonin receptor that our research shows is important for anti-depressant behavior," said co-author Dr. Richard R. Neubig.

The study details the complex actions of a family of proteins, known as RGS proteins that act as brakes on neurotransmitter signaling.

Researchers created a mutant mouse to boost serotonin signalling at the 5HT1a receptor.

This was done by genetically inhibiting the activity of braking proteins.

Without the normal brake on serotonin signalling, these mutant mice showed antidepressive behaviour even without being given antidepressant drugs.

The mice were also more responsive to SSRIs.

According to the authors, further research could lead to drugs capable of inhibiting the RGS proteins and which would target the antidepressant signal where it is required on critical 5HT1a receptors.

The study appears in the journal Proceedings of the National Academy of Sciences.

Source: ANI
Advertisement

Advertisement
Advertisement

Latest Drug News

Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
Myeloma Drug: New Findings
In myeloma (blood cancer) cells, cancer-promoting potential of the fatty acid binding proteins was found to determine to be a valid target for myeloma therapeutics
Lower Dose of Acetaminophen Linked to Reduced Serious Liver Injury
Acute liver failure cases dropped after the Food and Drug Administration rule to lower the dosage of acetaminophen
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Scientists Reveal New Target for Antidepressants Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests